JB Chemicals & Pharmaceuticals reported a total income of Rs.618.96 crores during the period ended June 30, 2021, as compared to Rs 544.97 for the corresponding quarter last year. The total income for the period ended March 31, 2020, was Rs 553.80 crores.

The company has posted a net profit of Rs.118.87 crores for the period ended June 30, 2021, as against a net profit of Rs 119.42 crores for the corresponding quarter last year. The net profit for the quarter ended March 31, 2021, was 100.61 crores.

The company has reported EPS of Rs.15.38 for the period ended June 30, 2021, as compared to Rs 15.45 for the corresponding quarter last year. The EPS for the period ended March 31, 2021, was Rs 13.02.

Commenting on financial results, Mr. Nikhil Chopra, CEO and Wholetime Director, JBCPL said, “The organisation continues its strong performance well in the first quarter of the financial year. On the domestic front, we are one of the fastest-growing companies in the industry. Our new GoTo-Market(GTM) model has been implemented and early signs are encouraging, which is reflected in the strong performance of flagship brands and new launches. While demand trends in international business continue to be volatile (given the COVID situation); our key markets like US, S Africa have outperformed and even Russia/ CIS are seeing gradual signs of revival. We expect the performance to improve in select pockets of our international business. Going forward, our priority continues to build on cost efficiency measures while maintaining the same growth momentum.

The company said in a release that the organization continues to perform well with revenue momentum continuing to remain strong.  Highest ever quarterly revenue recorded during the first quarter of FY21, despite lockdowns in key markets and supply chain challenges. Domestic formulations business records 39 % growth while the International business revenue was largely flat as compared to Q1 FY21. As per MAT June 2021 IQVIA data, Domestic Formulations maintains secular outperformance compared to industry growth rates, driven by strength in chronic segments and expanding prescriber coverage.  Uncertainty because of the second wave of COVID-19 impacted growth in certain geographies in the international market during the quarter. Gross Margin profile continues to remain healthy at 64 % aided by good product mix and finally, the EBITDA margin remains strong despite cost base returning to normal in level of operations in Q1FY22.